TY - JOUR
T1 - Venous stasis-induced fibrinolysis prevents thrombosis in mice
T2 - Role of A2-antiplasmin
AU - Singh, Satish
AU - Houng, Aiilyan K.
AU - Reed, Guy L.
N1 - Funding Information:
This work was funded in part by grants from the National Institutes of Health, National Institute of Neurological Disorders and Stroke (NS089707) and the National Institutes of Health, National Heart, Lung, and Blood Institute (HL092750) to G.L.R.
Publisher Copyright:
© 2019 by The American Society of Hematology
PY - 2019/9/19
Y1 - 2019/9/19
N2 - Stasis of venous blood triggers deep vein thrombosis by activating coagulation, yet its effects on the fibrinolytic system are not fully understood. We examined the relationship between stasis, fibrinolysis, and the development of experimental venous thrombosis. Effects of stasis-induced deep vein thrombosis and fibrinolysis on thrombosis were examined by inferior vena cava ligation in congenic mice with and without a2-antiplasmin (a2AP), the primary inhibitor of plasmin. Venous thrombus weights were measured and thrombus composition was determined by Martius scarlet blue and immunofluorescence staining. Venous thrombi from a2AP1/1mice contained plasminogen activators, plasminogen activator inhibitor-1, plasminogen, and a2AP, which changed with thrombus age. Normal, a2AP1/1mice developed large, occlusive thrombi within 5 hours after ligation; thrombi were even larger in plasminogen-deficient mice (P < .001). No significant thrombus formation was seen in a2AP2/2 mice (P < .0001) or in a2AP1/1mice treated with an a2AP-inactivating antibody (P < .001). Venous stasis activated fibrinolysis, measured by D-dimer levels, in a2AP2/2 mice vs a2AP1/1mice (P < .05). Inhibition of fibrinolysis by the indirect plasmin inhibitor «-aminocaproic acid or by a2AP restored thrombosis in a2AP2/2 mice. In addition to its effects on acute thrombosis, thrombus formation was also markedly suppressed in a2AP2/2 mice vs a2AP1/1mice (P < .0001) 1, 7, and 14 days after ligation. We conclude that experimental venous stasis activates the fibrinolytic system to block the development of venous thrombosis. Suppression of fibrinolysis by a2AP appears essential for stasis-induced thrombus development, which suggests that targeting a2AP may prove useful for preventing venous thrombosis.
AB - Stasis of venous blood triggers deep vein thrombosis by activating coagulation, yet its effects on the fibrinolytic system are not fully understood. We examined the relationship between stasis, fibrinolysis, and the development of experimental venous thrombosis. Effects of stasis-induced deep vein thrombosis and fibrinolysis on thrombosis were examined by inferior vena cava ligation in congenic mice with and without a2-antiplasmin (a2AP), the primary inhibitor of plasmin. Venous thrombus weights were measured and thrombus composition was determined by Martius scarlet blue and immunofluorescence staining. Venous thrombi from a2AP1/1mice contained plasminogen activators, plasminogen activator inhibitor-1, plasminogen, and a2AP, which changed with thrombus age. Normal, a2AP1/1mice developed large, occlusive thrombi within 5 hours after ligation; thrombi were even larger in plasminogen-deficient mice (P < .001). No significant thrombus formation was seen in a2AP2/2 mice (P < .0001) or in a2AP1/1mice treated with an a2AP-inactivating antibody (P < .001). Venous stasis activated fibrinolysis, measured by D-dimer levels, in a2AP2/2 mice vs a2AP1/1mice (P < .05). Inhibition of fibrinolysis by the indirect plasmin inhibitor «-aminocaproic acid or by a2AP restored thrombosis in a2AP2/2 mice. In addition to its effects on acute thrombosis, thrombus formation was also markedly suppressed in a2AP2/2 mice vs a2AP1/1mice (P < .0001) 1, 7, and 14 days after ligation. We conclude that experimental venous stasis activates the fibrinolytic system to block the development of venous thrombosis. Suppression of fibrinolysis by a2AP appears essential for stasis-induced thrombus development, which suggests that targeting a2AP may prove useful for preventing venous thrombosis.
UR - http://www.scopus.com/inward/record.url?scp=85072509224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072509224&partnerID=8YFLogxK
U2 - 10.1182/blood.2019000049
DO - 10.1182/blood.2019000049
M3 - Article
C2 - 31395599
AN - SCOPUS:85072509224
SN - 0006-4971
VL - 134
SP - 970
EP - 978
JO - Blood
JF - Blood
IS - 12
ER -